One particular type of BRAF mutation, called BRAF V600E, is present in around 5% to 10% of patients with metastatic colorectal cancer. Historically, metastatic colorectal cancer driven by a BRAF ...

Braftovi is a small molecule inhibitor of proteins with the BRAF V600E mutation, which can lead to activation of signaling pathways that drive certain cancers, including colorectal cancer.

Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6. Dr. Marwan G. Fakih discussed the FDA approval of ...

In this video, Arvind N. Dasari, MD, MS, discussed the phase 3 results from the BREAKWATER trial presented at ASCO Gastrointestinal Cancers Symposium.

as well as an increase in overall survival (OS), when used as a first-line treatment for colorectal cancer with BRAF V600E mutations. Both results were "clinically meaningful," according to a ...

In patients with metastatic colorectal cancer harboring a BRAF V600E mutation, the combo not only staved off disease progression but it also significantly extended patients’ lives compared with ...

Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has ... the combination in mCRC patients living with a BRAF V600E mutation who are treatment-naive. The top-line data also ...

in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation. The data is strongshowing a statistically significant and ...

More information: Scott Kopetz et al, Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial, Nature Medicine (2025). DOI: 10.1038/s41591-024-03443-3 ...